1[1]Carli P, Cattaneo A, Pimpinelli N, et al. Immunohistochemical evidence of skin immune system involvement in vulvar lichen sclerosus et atrophicus[J]. Dermatologica, 1991,182 (1):18-22.
2[2]Remero LI, Pincus SH. In situ localization of interleukin-6 in normal skin and atrophic cutaneous disease[J]. Int Arch Allergy Immunol,1992,99(1):44-49.
3[3]Carli P, Moretti S, Spallanzani A, et al. Fibrogenic cytokines in vulvar lichen sclerosus. An immunohistochemical study[J]. J Reprod Med, 1997,42(3): 161-165.
4[4]Lukowsky A, Muche JM, Sterry W, et al. Detection of expanded T cell clones in skin biopsy samples of patients with lichen sclerosus et atrophicus by T cell receptor-gamma polymerase chain reaction assays[J]. J Invest Dermatol, 2000, 115(2): 254-259.
5[5]Gross T, Wagner A, Ugurel S, et al. Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus[J].Dermatology, 2001, 202(3): 198-202.
6[6]Scrimin F, Rustja S, Radillo O, et al. Immunological study of vulvar lichen sclerosus: preliminary considerations[J]. Allerg Immunol Paris, 1993,25(1):22-23.
7[7]Clifton MM, Garner IB, Kohler S. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus:evidence for loss of androgen receptors in lesional epidermis[J]. J Am Acad Dermatol, 1999, 41(1): 43-46.
8[8]Zarcone R, Vicinanza G, Bellini P, et al. Drug treatment in vulvar lichen sclerosus[J]. Minerva Ginecol, 1996,48(10):441-444.
9[9]Joura EA, Zeisler H, Bancher-Todesca D. et al. Short-term effects of topical testosterone in vulvar lichen sclerosus [J]. Obstet Gynecol, 1997, 89(2):297-299.
10[10]Sidorenko IuS, Nerodo GA, Cherniavskaia GIa, et al. Endogenous factors in the development of leukoplakia and kraurosis vulvae[J].Vopr Onkol, 1990,36(10):1210-1214.
